NCT07156253

Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors

A Phase Ib Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SYN818 With Olaparib in Patients With Locally Advanced or Metastatic Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 110 (estimated)
• Sponsor: Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors

Detailed description

This study is a Phase Ib, open-label, multicentre study of SYN818 with Olaparib administered orally in patients with locally advanced or metastatic solid tumors harboring mutations in BRCA and/or defects in the homologous recombination repair (HRR) pathway

Conditions

• Metastatic Solid Tumor
• Ovarian Cancer
• Breast Cancer
• BRCA 1 /2 and / or HRD
• Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	SYN818 and Olaparib will be administered	Patients will orally receive SYN818 and Olaparib

Timeline

• Start date: 2025-08-26
• Primary completion: 2028-08-25
• Completion: 2029-02-25
• First posted: 2025-09-05
• Last updated: 2025-09-05

Locations

2 sites across 1 country: China